title: Tissue distribution and elimination after oral and intravenous administration of different titanium dioxide nanoparticles in rats.
abstract: OBJECTIVE
  The aim of this study was to obtain kinetic data that can be used in human risk assessment of titanium dioxide nanomaterials.
  
  
  METHODS
  Tissue distribution and blood kinetics of various titanium dioxide nanoparticles (NM-100, NM-101, NM-102, NM-103, and NM-104), which differ with respect to primary particle size, crystalline form and hydrophobicity, were investigated in rats up to 90 days post-exposure after oral and intravenous administration of a single or five repeated doses.
  
  
  RESULTS
  For the oral study, liver, spleen and mesenteric lymph nodes were selected as target tissues for titanium (Ti) analysis. Ti-levels in liver and spleen were above the detection limit only in some rats. Titanium could be detected at low levels in mesenteric lymph nodes. These results indicate that some minor absorption occurs in the gastrointestinal tract, but to a very limited extent.Both after single and repeated intravenous (IV) exposure, titanium rapidly distributed from the systemic circulation to all tissues evaluated (i.e. liver, spleen, kidney, lung, heart, brain, thymus, reproductive organs). Liver was identified as the main target tissue, followed by spleen and lung. Total recovery (expressed as % of nominal dose) for all four tested nanomaterials measured 24 h after single or repeated exposure ranged from 64-95% or 59-108% for male or female animals, respectively. During the 90 days post-exposure period, some decrease in Ti-levels was observed (mainly for NM-100 and NM-102) with a maximum relative decrease of 26%. This was also confirmed by the results of the kinetic analysis which revealed that for each of the investigated tissues the half-lifes were considerable (range 28-650 days, depending on the TiO(2)-particle and tissue investigated). Minor differences in kinetic profile were observed between the various particles, though these could not be clearly related to differences in primary particle size or hydrophobicity. Some indications were observed for an effect of crystalline form (anatase vs. rutile) on total Ti recovery.
  
  
  CONCLUSIONS
  Overall, the results of the present oral and IV study indicates very low oral bioavailability and slow tissue elimination. Limited uptake in combination with slow elimination might result in the long run in potential tissue accumulation.
authors.forename: Liesbeth
authors.initials: L
authors.lastname: Geraets
authors.forename: Agnes G
authors.initials: AG
authors.lastname: Oomen
authors.forename: Petra
authors.initials: P
authors.lastname: Krystek
authors.forename: Nicklas R
authors.initials: NR
authors.lastname: Jacobsen
authors.forename: Håkan
authors.initials: H
authors.lastname: Wallin
authors.forename: Michel
authors.initials: M
authors.lastname: Laurentie
authors.forename: Henny W
authors.initials: HW
authors.lastname: Verharen
authors.forename: Esther F A
authors.initials: EF
authors.lastname: Brandon
authors.affiliation: National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA, Bilthoven, The Netherlands. wim.de.jong@rivm.nl.
authors.forename: Wim H
authors.initials: WH
authors.lastname: de Jong
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D003460:Crystallization; D005260:Female; D057927:Hydrophobic and Hydrophilic Interactions; D007275:Injections, Intravenous; D008099:Liver / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D008198:Lymph Nodes / Q000378:metabolism; D008297:Male; D053768:Metal Nanoparticles; D010316:Particle Size; D017208:Rats, Wistar; D018570:Risk Assessment; D013154:Spleen / Q000378:metabolism; D014018:Tissue Distribution; D014025:Titanium / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000633:toxicity
chemical_list: C009495:titanium dioxide; D014025:Titanium